Targeting the epidermal growth factor receptor in colorectal carcinoma

Cancer Nursing

Volumn 30, Issue 4 SUPPL. 1, 2007, Pages

  Kurtin, Sandra E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acneiform rash; Adverse effects, diarrhea; Adverse effects, skin; Cetuximab; Colorectal cancer; Epidermal growth factor receptor inhibitor; Erlotinib; Gefitinib; Interstitial lung disease; Panitumumab

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CETUXIMAB; CLINDAMYCIN; EKI 569; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROMYCIN; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; FLUTICASONE PROPIONATE; FOLINIC ACID; GEFITINIB; HYDROCORTISONE; IRINOTECAN; LAPATINIB; LIDOCAINE; MATUZUMAB; METRONIDAZOLE; OXALIPLATIN; PANITUMUMAB; PIMECROLIMUS; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TARGETING; HUMAN; HYPOMAGNESEMIA; INTERSTITIAL LUNG DISEASE; LUNG CANCER; NAUSEA; NEUTROPENIA; NURSING; ONYCHOLYSIS; PARONYCHIA; PRIORITY JOURNAL; PROTEIN TARGETING; PRURITUS; REVIEW; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; XEROSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34547557983     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NCC.0000281757.78081.74     Document Type: Review

References (56)

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta, Ga: American Cancer Society; 2006. Available at: http://www.cancer.org/ downloads/STT/CAFF2006PWSecured.pdf. Accessed December 7, 2006.
2. National Comprehensive Cancer Network. Colon and rectal cancer - chemotherapy for advanced or metastatic colon cancer. From NCCN treatment guidelines. Available at: http://www.nccn.org/patients/patient_gls/asp/ ASP_Script_showTree/SVGAframeset.asp_pg=colon&idChart=8&bkG=. Accessed December 7, 2006.
3. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
4. Wilkes GM. Therapeutic options in the management of colon cancer: 2005 update. Clin J Oncol Nurs. 2005;9(1):31-44.
5. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 2005;10:250-261.
6. Saltz LB, Cox JV, Blanke C, et al, for the Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905-914.
7. Center for Drug Evaluation and Research. Eloxatin information. Available at: http://www.fda.gov/cder/drug/infopage/eloxatin/default.htm. Accessed December 7, 2006.
8. Center for Drug Evaluation and Research. FDA approves Vectibix (panitumumab) to treat metastatic colorectal cancer. Available at: www.fda.gov/cder/offices/OODP/whatsnew/panitumumab.htm. Accessed January 22, 2007.
9. Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-1214.
10. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
11. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
12. Kohne C, Van Cutsem E, Wils J, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group Study 40986. Proc Am Soc Clin Oncol. 2003;22:1018. [abstr].
13. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment of metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047.
14. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
15. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.
16. Peeters M, Van Cutsem E, Siena S, et al, The Panitumumab Study Team. A phase 3, multicenter, randomized controlled (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Presented at: 97th American Association for Cancer Research Annual Meeting; April 1-5, 2006; Washington, DC. Abstract CP-1. Available at: http://app2.capitalreach.com/esp1204/servlet/tc?cn=aacr&c=10165&s= 20323&e=5641&&autoRegRBI=1&m=1&espbr=95. Accessed January 25, 2007.
17. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94:1593-1611.
18. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803-812.
19. Harari PM, Huang S-M. Modulation of molecular targets to enhance radiation. Clin Cancer Res. 2000;6:2323-2325.
20. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193-216.
21. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7:2958-2970.
22. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 2001;19(18 Suppl):32S-40S.
23. US Food and Drug Administration. FDA News: FDA approves Erbitux for colorectal cancer. Available at: http://www.fda.gov/bbs/topics/NEWS/2004/ NEW01024.html. Accessed January 22, 2007.
24. ClinicalTrials.gov Web site. Effects of matuzumab in combination with pemetrexed for the treatment of advanced lung cancer. Available at: http://www.clinicaltrials.gov/show/NCT00111839. Accessed December 8, 2006.
25. Chen J, Smith M, Kolinsky K, et al. Antitumour activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. Cancer Chemother Pharmacol. 2007;59(5):651-659.
26. Tarceva® (erlotinib) tablets [prescribing information]. Melville, NY: OSI Pharmaceuticals Inc; and San Francisco, Calif: Genentech, Inc; 2005.
27. Wolpin BM, Clark JW, Meyerhardt JA, et al. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6:208-213.
28. Iressa® (gefitinib) tablets [prescribing information]. Wilmington, Del: AstraZeneca Pharmaceuticals LP; 2005.
29. Hoekstra R, Dumez H, Eskens FA, et al. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2005;11:6908-6915.
30. Erlichman C, Hidalgo M, Boni JP, et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol. 2006;24:2252-2260.
31. Nemunaitis J, Eiseman I, Cunningham C, et al. Phase I clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res. 2005;11:3846-3853.
32. Erbitux® (cetuximab) [prescribing information]. Branchburg, NJ: ImClone Systems Incorporated; and Princeton, NJ: Bristol-Myers Squibb Company; 2006.
33. ClinicalTrials.gov Web site. Information on clinical trials and human research studies: trial list for colorectal cancer and EGFR therapy. Available at: http://www.clinicaltrials.gov/ct/search;jsessionid= 253ED68908F9EB4CF6FDDBB3D5029FB6?term=egfr+colorectal+cancer. Accessed December 8, 2006.
34. Rothenberg ML, LaFleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol. 2005;23:9265-9274.
35. Mackenzie MJ, Hirte HW, Glenwood G, et al. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs. 2005;23:165-170.
36. Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23:5305-5313.
37. Vectibix™ (panitumumab) [prescribing information]. Thousand Oaks, Calif: Amgen Inc; 2006.
38. Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol. 2004;24(14S):3510. [Abstract].
39. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803-1810.
40. Tabernero JM, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. J Clin Oncol. 2004;22(14S):3512. [Abstract].
41. Venook A, Niedzwiecki D, Holis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol. 2006;24(18S part 1):3509. [Abstract].
42. Messersmith WA, Laheru DA, Senzer NN, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res. 2004;10:6522-6527.
43. Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol. 2006;24:656-662.
44. Meyerhardt JA, Heseltine D, Oginao S, et al. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6:59-65.
45. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004;10:6487-6501.
46. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006;24:2158-2163.
47. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1:18-24.
48. Kohne C-H, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol. 2001;12:435-442.
49. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346.
50. Fish-Steagall A, Searcy P, Sipples R. Clinical experience with anti-EGFR therapy. Semin Oncol Nurs. 2006;22(1 Suppl 1):10-19.
51. Khoukaz T. Administration of anti-EGFR therapy: a practical review. Semin Oncol Nurs. 2006;22(1 Suppl 1):20-27.
52. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238-3247.
53. Meropol NJ, Berlin J, Hecht JR, et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2003:256. [abstr].
54. O'Keeffe P, Parrilli M, Lacouture ME. Toxicity of targeted therapy: focus on rash and other dermatologic side effects. Oncol Nurs Educ. 2006;20(103 Suppl 12):1-6.
55. Robert C, Soria J-C, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491-500.
56. Suh K-Y, Kindler HL, Medenica M, Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol. 2006;154:191-192.